The Motley Fool
01 Aug 2026, 11:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Bristol Myers Squibb faces material patent expirations for Revlimid and Pomalyst in 2026, and Eliquis in 2028. — Patent loss typically leads to significant revenue drops, putting direct pressure on the company's top and bottom lines.
-0.60Bristol Myers Squibb's current valuation is low, with a P/E ratio of 17.5x compared to the industry average of 25x. — A low P/E relative to peers suggests the stock may be undervalued, attracting value investors.
+0.30The company offers a high dividend yield of approximately 4%, significantly exceeding the S&P 500 average of 1%. — High yields provide a floor for the stock price and appeal to income-focused investors during periods of uncertainty.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Bristol Myers Squibb has a pipeline of drug candidates in rare diseases, immunology, and cancer that could offset patent losses. — Successful new drug approvals act as the primary catalyst for long-term growth and recovery in pharmaceutical stocks.
+0.20Which stocks this story touches
The article notes attractive value and dividends, but warns of upcoming revenue pressure due to patent expirations.
The company faces a material drop in revenue from Eliquis due to patent expiration in 2028.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
The Motley Fool
4h ago
